secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-06-18T11:00:03+00:00
Accession:  0001645113-26-000053
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM
--------------------------------------------------------------------------------

- Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.
- 981 patients enrolled; 25% did not initiate maintenance phase across both arms.
- 1-/2-/3-year survival rates: Early Start 70.9%/33.9%/22.5%; Maintenance 72.0%/31.6%/18.4%.
- No new safety signals; TTFields with chemoradiation was well-tolerated.
- Results accepted for presentation at ASTRO 2026 Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/0001645113-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/nvcr-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer